SCHEMBL17407196

SCHEMBL17407196

Cc1cc(-c2csc(N)n2)cc(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 6/20 0.55
MPL P40238 3/20 0.49
ALDH1A1 P00352 7/20 0.44
RAB9A P51151 5/20 0.44
ALOX5 P09917 1/20 0.44
MAPT P10636 6/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NFKB1 P19838 2/20 0.41
GFER P55789 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AR P10275 1/20 0.41
NOTUM Q6P988 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278201 0.89 LTA4H (0.58) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL27985361 0.83 LTA4H (0.54) LTA4HALDH1A1RAB9AALOX5MAPT
SCHEMBL474188 0.83 MAPT (0.55) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL18724007 0.81 LTA4H (0.51) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL18724009 0.81 ALDH1A1 (0.54) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL474280 0.81 MPL (0.52) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL29654146 0.81 LTA4H (0.51) LTA4HMPLALDH1A1RAB9AALOX5
Bromide SCHEMBL8360770 0.81 MAPT (0.54) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL17386849 0.81 RAB9A (0.55) LTA4HMPLALDH1A1RAB9AALOX5
SCHEMBL23364762 0.79 MPL (0.53) LTA4HMPLALDH1A1RAB9AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49111-E1 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2022-06-21 US disclosed
EP-3153511-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES ASTELLAS PHARMA INC (JP) 2019-05-15 EP disclosed
EP-3196200-B1 2-AMINOTHIAZOLE DERIVATIVES OR SALT THEREOF AS MUSCARINIC M3 LIGANDS FOR THE TREATMENT OF BLADDER DISEASES ASTELLAS PHARMA INC (JP) 2019-05-08 EP disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 US disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 US disclosed
US-9844549-B2 2-aminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-12-19 US disclosed
US-9844549-B2 2-aminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-12-19 US disclosed
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-10-12 US disclosed
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-10-12 US disclosed
EP-3196200-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2017-07-26 EP disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 US disclosed
EP-3153511-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2017-04-12 EP disclosed
US-9562044-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-02-07 US disclosed
US-20160002218-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002218-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, CHRM5 LTA4H 944/4885MPL 3292/4885ALDH1A1 1565/4885
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 LTA4H 1000/4885MPL 3647/4885ALDH1A1 1551/4885
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 LTA4H 850/4885MPL 3786/4885ALDH1A1 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.